Cargando…

Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials

Spleen tyrosine kinase (Syk) signaling is central to phagocytosis‐based, antibody‐mediated platelet destruction in adults with immune thrombocytopenia (ITP). Fostamatinib, an oral Syk inhibitor, produced sustained on‐treatment responses in a phase 2 ITP study. In two parallel, phase 3, multicenter,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bussel, James, Arnold, Donald M., Grossbard, Elliot, Mayer, Jiří, Treliński, Jacek, Homenda, Wojciech, Hellmann, Andrzej, Windyga, Jerzy, Sivcheva, Liliya, Khalafallah, Alhossain A., Zaja, Francesco, Cooper, Nichola, Markovtsov, Vadim, Zayed, Hany, Duliege, Anne‐Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055608/ https://www.ncbi.nlm.nih.gov/pubmed/29696684 http://dx.doi.org/10.1002/ajh.25125

Ejemplares similares

Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program
por: Bussel, James B., et al.
Publicado: (2019)

Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib
por: Cooper, Nichola, et al.
Publicado: (2021)

Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia
por: Boccia, Ralph, et al.
Publicado: (2020)

Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion
por: Lucchesi, Alessandro, et al.
Publicado: (2023)

88. Fostamatinib for the Treatment of Hospitalized Patients With COVID-19 Who Required Oxygen Supplementation: Results of a Phase 3 Trial
por: Gotur, Deepa B, et al.
Publicado: (2023)

Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA
por: McKeage, Kate, et al.
Publicado: (2018)

Two Refractory Immune Thrombocytopenia Case Reports Showing Responsiveness to Fostamatinib
por: Innao, Vanessa, et al.
Publicado: (2023)

Successful Treatment with Thrombopoietin Receptor Agonist in Avoiding Splenectomy for Patients with Chronic Refractory Immune Thrombocytopenia
por: Khalafallah, Alhossain, et al.
Publicado: (2012)

Correction to: Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA
por: McKeage, Kate, et al.
Publicado: (2018)

Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?
por: Lucchini, Elisa, et al.
Publicado: (2019)

The Efficacy and Safety of Fostamatinib in Elderly Patients with Immune Thrombocytopenia: A Single-Center, Real-World Case Series
por: Liu, Jessica, et al.
Publicado: (2022)

Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia
por: Khalafallah, Alhossain, et al.
Publicado: (2010)

561. Phase 3 Trial of Fostamatinib for the Treatment of COVID-19: Repurposing an Immunomodulatory Drug Previously Approved for Immune Thrombocytopenia
por: Mallat, Ziad, et al.
Publicado: (2021)

Concurrent Hairy Cell Leukemia and Metastatic Merkel Cell Carcinoma
por: Prakash, Ajay, et al.
Publicado: (2018)

Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs
por: Harbi, Maan H., et al.
Publicado: (2022)

Iron Deficiency Anaemia in Pregnancy and Postpartum: Pathophysiology and Effect of Oral versus Intravenous Iron Therapy
por: Khalafallah, Alhossain A., et al.
Publicado: (2012)

Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents
por: Lengel, Dave, et al.
Publicado: (2015)

Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies
por: Martin, Paul, et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406
por: Matsukane, Ryosuke, et al.
Publicado: (2022)

Romiplostim use in pregnant women with immune thrombocytopenia
por: Bussel, James B., et al.
Publicado: (2022)

Management of thrombocytopenia
por: Izak, Marina, et al.
Publicado: (2014)

P1614: TAPERING SCHEME AND SUSTAINED RESPONSE IN PATIENTS WITH ITP TREATED WITH FOSTAMATINIB
por: Mingot-Castellano, María Eva, et al.
Publicado: (2023)

The spleen in immune thrombocytopenia
por: Geyer, Julia T., et al.
Publicado: (2018)

Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury
por: Tabassum, Neha, et al.
Publicado: (2020)

The Cardiovascular Risks of Fostamatinib in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
por: Chen, Yuehong, et al.
Publicado: (2021)

High Serum Erythropoietin and Ferritin Levels in Conjunction with Anemia Response in Malignant Lymphoma
por: Omari, Sofia, et al.
Publicado: (2011)

An Unusual Presentation of Desmoplastic Small Round Cell Tumour of the Abdomen: Morphological, Immunohistochemical, Ultrastructural, and Molecular Studies
por: Angunawela, Preethika, et al.
Publicado: (2011)

In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib
por: Rolf, Michael G, et al.
Publicado: (2015)

Neoplasm Risk in Patients With Rheumatoid Arthritis Treated With Fostamatinib: A Systematic Review and Meta-analysis
por: Chen, Yuehong, et al.
Publicado: (2022)

Sustained response off therapy after fostamatinib: A chronic refractory ITP case report
por: Auteri, Giuseppe, et al.
Publicado: (2023)

P1613: REAL-WORLD USE OF FOSTAMATINIB IN FRANCE. INTERIM RESULTS OF A NATIONAL REGISTRY.
por: Moulis, Guillaume, et al.
Publicado: (2023)

P1589: PATIENT (PT) AND PHYSICIAN (MD) PERCEPTIONS OF THE BURDEN OF IMMUNE THROMBOCYTOPENIA (ITP) AND ITS MANAGEMENT: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) 2.0
por: Cooper, Nichola, et al.
Publicado: (2023)

A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia
por: Grainger, John, et al.
Publicado: (2022)

Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic
por: Strich, Jeffrey R, et al.
Publicado: (2020)

Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?
por: Saha, Sovan, et al.
Publicado: (2022)

Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration
por: Wang, Mingyao, et al.
Publicado: (2022)

Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study
por: Kuter, David J., et al.
Publicado: (2022)

Immune Thrombocytopenia: Are We Stuck in the Mud or Is There Light at the End of the Tunnel?
por: Bussel, James, et al.
Publicado: (2019)

Extramedullary Plasmacytoma of the Tonsil with Nodal Involvement
por: Bazaadut, Simon, et al.
Publicado: (2010)

Thrombocytopenia in Virus Infections
por: Raadsen, Matthijs, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c2uk18aonrt5jbk43b6nrta6m8